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1. Introduction 
A nucleotide analog 5-bromo-2’-deoxyuridine (BrdU) is a genotoxic compound that is 
incorporated into DNA [1]. When rodent fetuses are exposed to BrdU prenatally, the cortical 
development is profoundly affected. Cortical abnormalities induced by prenatal BrdU are 
shown as a reduction in thickness of the cerebral cortex [2]. An induction of apoptotic cell 
death in the mouse and rat fetal brain [3, 4] and disturbance to normal migration that 
induces abnormal composition of cortical glutamatergic or GABAergic neurons have been 
demonstrated [4]. Mouse data suggest that the prenatal BrdU treatment induced apoptotic 
phenomenon without sex difference (Figure 1). 
Adult rats that were prenatally treated with BrdU show locomotor hyperactivity. The 
hyperactivity was observed in both male and female rats and was characterized as an 
increase in spontaneous motor activity during dark cycles observed in home cages [5] and 
novelty-induced hyperlocomotion in the open-field [5 - 8]. This abnormal behavior is 
exacerbated by the treatment with dopamine (DA) agonist, methylphenidate, which 
indicates that animals acquired hypersensitivity to dopaminergic stimuli [5, 8]. Recently 
proposed animal models for schizophrenia that knock-out candidate genes for this disease, 
such as neurotensin receptors [9] or calcium/calmodulin-dependent kinase II alpha [10], 
show hyperactive phenotypes and abnormal striatal DA function while mice overexpressing 
DA D2 receptors in the striatum show unaltered locomotor activity [11]. In a major 
psychiatric disorder schizophrenia, disturbance in cortical development and subcortical 
dopaminergic abnormality have been proposed [12] and they induces hypothetical 
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pathology in this disease “a prefrontal hypodopaminergia and a subcortical 
hyperdopaminergia” [13]. We propose that prenatal BrdU-treated rats is an animal model of 
schizophrenia based on findings that 1) the malformation of the cerebral cortex and 2) DA 
hypersensitivity. 
 
Figure 1. Incidence of cell death in fetal mouse brains on the embryonic day 12 after the treatment with 
BrdU at the embryonic day 11 without indenfying sex. Apoptotic features were inspected under Nissl 
stain. Data were indicated as percents of numbers of apoptotic cells; C and B in parentheses indicates 
control and BrdU-treated animals. Horizontal bars indicate means. Significant increases in the numbers 
of apoptotic cell death were indicated as asterisks: *, **; P < 0.05, 0.01, respectively vs. controls. Results 
suggest that apoptotic cell death occurred similarly in fetal brains between males and females because 
values in % cell death in BrdU-treated brains in sample of mixed males and females scattered without 
clustering. FCx, the frontal cortex; CCx, the central cortex; PCx, the posterior cortex; St, the striatum; 
Hipp, the hippocmpus; A-Th, the anterior thalamus; P-Th, the posterior thalamus; A-Hy, the anterior 
hypothalamus; P-Hy, the posterior thalamus; AMY, the amygdala; MB, the mamillary body; Pretect, the 
pretectum; MT, the mecencephalic tegmentum; SN+VTA; The sunbtantia nigra + the ventral tegmental 
area; SC, the superior colliculus; IC; the inferior colliculus; Isth, the inthmus; Cereb, the cerebellum. 
Sexual dimorphism in animal models of mental disorders is interested theme to be explored 
because sexual difference has been reported in clinical features in such disorders including 
schizophrenia. Emergence of abnormal symptoms in human mental illnesses has been 
known to be relevant to the beginning of puberty and this phenomenon appears to be 
influenced by gonadal hormones [14]. Gender differences in the age-of-onset and prevalence 
of mental disorders indicate an involvement of sex hormones in schizophrenia. 
Schizophrenia is more likely to emerge during adolescence or shortly afterwards and the 
first symptoms of schizophrenia emerge earlier in men than women [15]. This is more direct 
evidence for the involvement of sex steroids is the observation that adult women with 
schizophrenia have worse psychiatric symptoms and increased rate of relapse when 
estrogen levels are low in premenstrual period, postparturition or postmenopausal period 
[16]. Furthermore, estrogen has been shown to improve recovery from acute psychotic 
symptoms and to reduce both positive and negative symptoms of schizophrenia [17]. In 
adult males with schizophrenia testosterone levels are reduced and are inversely correlated 
with negative symptoms [18]. Altered expression of estrogen receptor alpha putatively 
rendering them sex-steroid unresponsive or insensitive has been reported [19]. Blunted sex 
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steroid signaling has implications for both males and females with schizophrenia, as 
testosterone can be converted directly into estrogen by brain aromatase and the lack of 
functional estrogen receptors is found in both males and females with schizophrenia. 
The changes in hormone levels that accompany sexual maturation in puberty are critically 
involved in the development of the monoaminergic system [20]. In animal studies, in 
addition to the well-known modulatory effects of estrogen or progesterone on DA 
neurotransmission or DA-related behavior [21 - 25], it has been reported that neuronal 
systems whose dysfunction mediates the emergence of psychotic-like behavior develops 
after the emergence of puberty, suggesting a role for gonadal hormones in the expression of 
pathological phenotypes [26, 27]. A study of rhesus macaques has demonstrated that intact 
adult animals display attenuated prepulse inhibition than animals given prepubertal 
castration [28]. In addition, results from studies of sexual dimorphic effects of prenatal stress 
in rats imply that the developing brain of female fetuses is less sensitive to maternal stress 
exposure than male ones, however, enhanced aggressive behavior or disturbed estrous cycle 
are observed [29]. Neonatal stress manipulation, maternal deprivation from pups, increases 
DA and 5-HT levels in the striatum in adulthood and the magnitude of changes are greater 
in males than females [30]. 
In this chapter, we introduce the development of this animal model, their behavioral and 
neurochemical characters. Then, we evaluate recent obtained data of sexual dimorphic 
changes in DA and serotonin (5-HT) metabolisms in the prenatally BrdU-treated rats, and 
effects of gonadectomy that was performed during the prepubertal period. 
2. Methods 
2.1. Animals, drug treatments and gonadectomy 
Sprague-Dawley rats were purchased from Charles River Laboratories (Tsukuba, Japan). 
They were housed in metal cages in a room in which the temperature and relative humidity 
were controlled at 24 ± 1°C and 50 ± 5%, respectively. Lights were turned on from 0700 to 
1900 h daily, and food and tap water were freely accessed. At 11 weeks of age, female rats 
were cohabited overnight with males. Females with sperm in their vaginal smears were 
regarded as pregnant, and were randomly assigned to the control or test groups. The day 
when the insemination was confirmed was designated as GD 0. BrdU (Sigma, St. Louis, MO) 
was suspended in 0.5% sodium carboxymethyl cellulose (CMC Na) and intraperitoneally 
administered to the test animals at 1300 h daily on GD 9 through 15. Females in the test group 
received a BrdU dose of 50 mg/kg, whereas control females subjected to the same regime 
received 0.5% CMC Na (5 ml/kg). The dosages were based on body weight on GD 9. The day 
of birth was designated postnatal day 0 (PND 0). On PND 1, each litter was reduced to eight 
animals; four males and four females. On PND 21, all offspring were weaned. At 10 weeks of 
age, one male and female animal obtained from an independent litter were sacrificed by 
decapitation and their brains were removed between 1600 and 1800 h. Each brain was 
subsequently dissected on ice. All tissues were stored at –80°C until the assay. We arranged 
other groups to investigate the effect of gonadectomy: the BrdU/GDX and BrdU/non-GDX 
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groups. Female pups obtained from BrdU-treated pregnant rats were used for this 
investigation. Female offspring assigned to the BrdU/GDX group were gonadectomized at 21 
days of age, while animals assigned to the BrdU/non-GDX group received a sham operation. 
2.2. Biochemical measurements 
DA, 5-HT and their major metabolites, dihydroxyphenylacetic acid (DOPAC), homovanilic 
acid (HVA), and 5-hydroxy-3-indolacetic acid (5-HIAA) were determined by reversephase 
high-performance liquid chromatography with electrochemical detection (HPLC-ECD) as 
previously described [31]. Briefly, the brain tissues were homogenized in 0.1 M perchloric acid 
containing 1 mM EDTA and 2 mM Na2S2Os. Chloroform was added, and the mixture was then 
centrifuged at 11752 x g for 30 min at 4°C. The supernatant was removed and injected into the 
HPLC system. The HPLC system consisted of an EP-300 pump (Eicom Co., Kyoto, Japan), an 
ODS C18 reverse-phase column (Eicompak MA-5ODS, 4.5• x 150 mm; Eicom Co.) and an 
ECD-300 electrochemical detector (Eicom Co.) with a graphite working electrode maintained 
at +0.7 V with respect to an Ag/AgCl reference electrode. The mobile phase was 0.035 M 
sodium acetate–0.05 M citric acid (pH=3.9) containing 1.1 mM octanesulfonate, 8.3 mM EDTA, 
and 15% methanol (v/v). As indices of DA turnovers, DOPAC/DA and HVA/DA ratios were 
calculated. As an index of 5-HT turnover, 5-HIAA/5-HT ratio was calculated. 
2.3. Evaluation of sexual behavior in offsprings 
At 15 weeks of age, male animals were presented with an ovariectomized female brought 
into sexual receptivity by sequential treatment with estradiol benzoate and followed 
progesterone. Musculine sexual behavior was evaluated in the numbers of mounts and 
latency to the first mount. After this observation, each male was cohabited with an treated 
female to evaluate fertility. 
2.4. Statistical analysis 
Data are shown as means ± S.E.M. Student’s t-tests and one-way ANOVA were applied for 
comparisons between two groups and three groups, respectively. Monoamine contents were 
formulated into percent values of controls before analysis for differences between Male-
BrdU, Female-BrdU and Female-BrdU-GDX because each group had independent controls. 
Post-hoc Tukey/Kramer tests was performed accompanied with one-way ANOVAs. Two-
way ANOVAs were applied to analyze two independent factors (Sex and BrdU) 
simultaneously. P values less than 0.05 were considered to be statistically significant. 
3. Results 
3.1. Behavioral and pharmacological aspects of prenatally BrdU-treated rats 
Behavioral and pharmacological aspects of prenatally BrdU-treated rats are summarized in 
Table 1. Spontaneous locomotor activity in the open-field was elevated both in male and 
female BrdU-treated rats when it was measured for 3 and 60 min [5, 8]. Activity in home 
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cages of BrdU-treated animals was also elevated both in males and females but this 
hyperactivity was found in the dark cycle but not in the light cycle. The characteristic 
hyperactivity in the open-field induced by prenatal BrdU treatment was challenged to be 
influenced with dopaminergic, serotonergic and noradrenergic agents; methylphenidate 
(DA agonist), SCH23390 (DA D1 receptor antagonist), sulpiride (DA D2 receptor antagonist), 
NAN190 (5-HT1A receptor antagonist), ketanserin (5-HT2A receptor antagonist), paroxetine 
(selective serotonin reuptake inhibitor) and desipramine (noradrenaline reuptake inhibitor) 
[5, 6]. The data were obtained in male rats. Methylphenidate facilitated hyperlocomotion 
shown in BrdU-treated rats dose-dependently. The dose of methylphenidate (1 mg/kg) that 
did not stimulate locomotion in controls elevated locomotor activity of BrdU-treated rats [5, 
8]. SCH23390 and NAN190 decreased activity in BrdU-treated rats but similar changes were 
also found in control rats. Effects of sulpiride and ketanserin on hyperactivity of the BrdU-
treated rats were not certain. However, paroxetine and desipramine suppressed 
hyperlocomotion of BrdU-treated rats dose-dependently without influencing the activity of 
controls [5]. These results suggest that BrdU exposed to fetus induced similar behavioral 
phenotype in male and female animals. The BrdU-treated animals seem to show behavioral 
hypersensitivity to a DA agonist. Inhibition of reuptake of 5-HT or noradrenaline seems to 
suppress locomotor activity specifically in BrdU-treated rats rather than antagonists to DA 
or 5-HT receptors. 
 
Table 1. Behavioral and pharmacological aspects of prenatally BrdU-treated rats 
3.2. Effects of prenatal BrdU treatment on DA and 5-HT and their metabolites in 
male and female offsprings 
In the frontal cortex, brain contents of 5-HT and 5-HIAA seem to elevate in BrdU-treated 
females but not in BrdU-treated males (Figure 2A). In the striatum, DA and DOPAC 
contents significantly decreased in BrdU-treated males while DA contents significantly 
elevated and DOPAC contents showed control levels in BrdU-treated females (Figure 2B). 
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BrdU-treated male rats shows prominent increases in striatal 5-HT and 5-HIAA while 5-HT 
levels were mildly elevated and 5-HIAA levels were comparable to controls’ values in BrdU-
treated females (Figure 2B). Significant reductions in DA and a significant reduction and a 
tendency to decrease in DOPAC contents were found in the hypothalamus of male and female 
BrdU-treated rats (Figure 2C). There were a significant reduction in HVA in females and a 
significant reduction in 5-HIAA in males in BrdU-treated animals in the midbrain (Figure 2D). 
 
Figure 2. Changes in tissue contents of monoamines and their metabolites in prenatally BrdU-treated 
rats. Data are indicated as percent values of controls. Statistical significance in difference between 
controls and BrdU-treated animals is indicated as symbols located at the top of columns; #, P < 0.05 vs. 
male controls; ##, P < 0.01 vs. male controls; §, P < 0.05 vs. female controls. Statistical significance in 
percent values between BrdU-treated males (Male-BrdU), BrdU-treated females (Female-BrdU) and 
BrdU-treated females that are given gonadectomy (Female-BrdU-GDX) is indicated as asterisks located 
between columns; *, P < 0.05; **, P < 0.01. 
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3.3. Effects of prenatal BrdU treatment and sex on rations of DOPAC/DA, 
HVA/DA and 5-HT 
There was no significant effect of BrdU or Sex on DOPAC/DA, HVA/DA or 5-HT in the 
frontal cortex (Figure 3A). In the striatum and the midbrain, significant effects of Sex on all 
measured turnover ratios and a significant effect of BrdU on 5-HIAA/5-HT ratio were 
detected (Figure 3B and D). There were significant effects of Sex on DOPAC/DA and 5-
HIAA/5-HT and a significant effect of BrdU on 5-HIAA/5-HT in the hypothalamus (Figure 
3C). Significant interaction of the two independent factors Sex and BrdU was detected in 
any measured values. There data suggest that prenatal BrdU affects 5-HT turnovers in the 
striatum, hypothalamus and midbrain in male and female offsprings in same manner. These 
brain regions seem to show intrinsic sexual differences in DA and 5-HT turnovers. 
3.4. Sexual dimorphism in the effects of prenatal BrdU treatment on DA and 5-
HT metabolism  
Statistical analysis indicated significant sexual dimorphic effects of prenatal BrdU on 
monoamines in the frontal cortex and the striatum but not in the hypothalamus and 
midbrain. There were significant differences in percent changes of 5-HT and 5-HIAA 
compared with control levels between male and female offspring in the frontal cortex 
(Figure 2A). In the striatum, significant differences in percent changes of DA, DOPAC and 
5-HIAA compared with control levels were detected between male and female offspring in 
the striatum (Figure 2B).  
3.5. Effects of prepubertal gonadectomy of BrdU-treated females on striatal 
monoamines 
Results were summarized in Table 2. No statistical difference in DA and DOPAC levels 
were found in the BrdU-treated females that gave gonadectomy prepubertally compared 
with the BruU-treated male and female rats without gonadectomy although marked 
differences in BrdU-induced changes were found in DA and DOPAC levels between male 
and female groups (Figure 2B). Significant differences in 5-HT and 5-HIAA levels were 
found in the BrdU-treated females with gonadectomy compared with the BrdU-treated 
males (Figure 2B), which were similar changes to the BrdU-treated females without 
gonadectomy. These results indicate abolishment of sexual dimorphism by prepubertal 
gonadectomy in effects of prenatal BrdU treatment on the DA system but not in the 5-HT 
system in the striatum.  
3.6. Disruption of sexual behavior in male offsprings from BrdU-treated dams 
Males in the BrdU group showed the significantly lowered number of mounts and aberrant 
latency of the first amount, which resulted in a significant decrease in the copulation and 
fertility [7]. 
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Figure 3. DOPAC/DA, HVA/DA and 5-HIAA/5-HT ratios in male controls (Male-Control), BrdU-
treated males (Male-BrdU), female controls (Female-Control) and BrdU-treated females (Female-BrdU). 
P values in applied two-way ANOVAs as factors of SEX and BrdU are incorporated in figures when 
results were statistically significant.  
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Table 2. A summary of sexual dimorphic effects of prenatal BrdU on the monoamine metabolism in the 
striatum 
4. Discussion 
The treatment with BrdU in the mid-pregnancy induced apoptotic cell death in fetal brains 
in rodents without sex difference. Offspring from prenatal BrdU-treatment showed 
prominent hyperactivity in familiar or novel environment after maturation, which was 
observed both in male and females. However, sexual behavior was disrupted in male 
offspring when they were prenatally treated with BrdU. In this animal model, sexual 
dimorphism in monoamine metabolism was revealed. Most obvious differences in 
monoamine metabolism between males and females were found in DA contents in the adult 
striatum; a decrease in males and an increase in females. While DA levels seem to be 
reduced in the frontal cortex similarly in males and females with prenatal BrdU treatment. 
Another sexual dimorphic effect was changes in 5-HT in the striatum and the frontal cortex. 
Increases in 5-HT were also found in the striatum in both sex but the magnitude in the 
changes were larger in males rather than in females. Increased 5-HT levels in the frontal 
cortex were obvious in females treated with BrdU prenetally but not in males. Therefore, 
prenatal BrdU treatment affects the striatal DA and 5-HT system most seriously in males. 
Effects of prenatal BrdU on the frontal cortical DA were moderate and the magnitude was 
similar in males and females. Cortical 5-HT was changes only in females. 
Results from the study of gonadectomy during prepubertal period demonstrated that the 
most obvious effect this manipulation was the abolishment sexual dimorphism in the effect 
of prenatal BrdU treatment on striatal DA. This phenomenon suggests that female-specific 
hormones are necessary for the development of striatal DA function in females. Female 
sexual hormones seem to exert a protective effect on DA neurons. In adult rodents, less 
neurotoxicity of 6-OHDA on midbrain DA neurons [32] and of methamphetamine on 
striatal DA neurons have been reported in females compared with males [33]. Furthermore, 
it has been suggested that susceptibility of the striatal dopaminergic system to 6-OHDA is 
reduced in male rats but enhanced in female rats by gonadectomy [34]. A development 
study indicates that gonadal hormones in female mice during the pre-pubertal period are 
necessary for estrogen to exert neuroprotective effects on the nigrostriatal dopaminergic 
system [35]. In addition, adrenalectomy accompanied with oral corticosterone replacement 
reduces anxiety-like behavior in male rats but it does not have significant effects on females 
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[36]. A study of rhesus macaques has demonstrated that intact animals display less prepulse 
inhibition than animals given prepubertal castration [28]. This study also reveals that 
testosterone levels are correlated with tyrosine hydroxylase levels in the putamen among 
intact animals, suggesting the attenuation of PPI by gonadal sex hormones is mediated by 
dopaminergic activity in striatal regions. In addition, methamphetamine increases latent 
inhibition in male rats while this agent decreases this behavior in female rats, suggesting 
that presynaptic dopaminergic function shows a sex difference [37]. Hence, striatal DA 
function, especially presynaptic DA function may be different intrinsically between males 
and females. 
The reduced DA and DOPAC in the striatum can be interpreted as a decreased total DA 
contents in presynaptic DA terminals that imply decrement of the number in DA 
presynaptic terminals or reduced DA synthesis rates. Ineffectiveness of DA receptor 
antagonists on hyperlocomotion found in BrdU-rats also supports abnormality in 
presynaptic function rather than postsynaptic DA receptors. In rodent, DA agonists usually 
facilitate locomotor activity. This study indicated opposite changes in striatal DA between 
males and females as an effect of prenatal BrdU while hyperlocomotion was obviously 
detected in both sex. Hence, the hyperlocomotion may be attributed to DA abnormality in 
the frontal cortex because the change was same in males and females. 
Schizophrenia includes multiple pathology in brain functions. Striatal dysfunction is 
thought to be a fundamental element in schizophrenia [13]. A study using functional 
magnetic resonance imaging (fMRI) in schizophrenic patients has demonstrated that 
increased coherent intrinsic activity in the dorsal striatum during psychosis is predictive for 
delusion and hallucination and increased activity during psychotic remission in the ventral 
striatum is predictive for blunted affect and emotional withdrawal [38]. A positron emission 
tomography (PET) study has indicated an increased DA D2/D3 receptor density in a 
restricted area in the striatum [39]. A double-blind PET study has indicated that D2 blockade 
in the striatum predicts antipsychotic response better than frontal, temporal, thalamic 
occupancy [40]. In addition, an involvement of the striatum in the cognitive impairment in 
schizophrenia has been proposed [41]. Furthermore, a study using recent molecular 
technique has shown that D2 receptor overexpression in the striatum results in a functional 
deficit in the GABAergic system and this result suggests that the postulated deficit in 
GABAergic function in schizophrenia could be secondary to alterations in the striatum DA 
system [42]. 
It is hypothesized that psychosis is viewed as a process of aberrant salience [43] and a 
central role of DA is to mediate the salience of environmental events an internal 
representations [44]. A study using resting-state functional MRI has indicated increased that 
coherent intrinsic activity in the dorsal striatum during psychosis is predictive for delusion 
and hallucination, and that increased activity during psychotic remission in the ventral 
striatum is predictive for blunted affect and emotional withdrawal [38]. A meta-analysis of 
imaging studies using PET or single-photon emission computed tomography (SPECT) has 
indicated that the locus of the largest dopaminergic abnormality in schizophrenia is 
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presynaptic, which affects DA synthesis capacity, baseline synaptic DA levels, and DA 
release although a primary target of current antipsychotic drugs is blockade of DA D2/D3 
receptors [45]. Higher DA concentration in the associative striatum in schizophrenia has 
been shown in a PET study using [11C]raclopride, and this result suggests that elevated 
subcortical DA function adversely affect performance of the dorsolateral prefrontal cortex in 
patients [46]. 18F-dopa uptake into the associative striatum is elevated in patients with 
prodromal symptoms of schizophrenia. This finding using PET indicates that DA 
overactivity in individuals with prodoromal psychotic symptoms [47]. This study also 
shows that striatal subdivision is negatively related to verbal fluency performance, but this 
is not the case for the limbic subdivision. Verbal fluency depends on prefrontal function 
[48]. The associative striatum regulates information flow to and from the prefrontal cortex 
[49, 50]. These findings provide a plausible mechanistic link between striatal dopaminergic 
dysfunction and prefrontal or executive dysfunction in schizophrenia. In addition, 5-HT2c 
receptor antagonist increased incentive motivation in an animal model of the negative-
symptoms of schizophrenia that was produced by increasing striatal-specific DA D2 receptor 
density [51]. These data suggests a possibility that the primary focus of pathology of 
schizophrenia is the striatum, which includes abnormal presynatic DA function, 
accompanied GABAergic and 5-HT dysfunction and parallel existence of aberrance in the 
prefrontal cortical function. 
Although further investigation is needed, this BrdU-animal could be a possible animal 
model for schizophrenia given that it includes abnormal presynaptic striatal DA function 
with sexual dimorphism and frontal cortical dysfunction relating to DA hypersensitivity. 
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